ETR:MDG1 Medigene (MDG1) Stock Price, News & Analysis €0.13 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medigene Stock (ETR:MDG1) Get Medigene alerts:Sign Up Key Stats Today's Range€0.13▼€0.1350-Day Range€0.13▼€0.1352-Week Range€1.60▼€5.51VolumeN/AAverage Volume306,207 shsMarket Capitalization€1.02 millionP/E RatioN/ADividend Yield1.31%Price TargetN/AConsensus RatingN/A Company Overview Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany. Read More Receive MDG1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDG1 Stock News HeadlinesMedigene bestellt neuen Vorstand - CEO Selwyn Ho gehtJuly 19, 2025 | finanznachrichten.dePTA-Adhoc: Medigene AG: Ausscheiden des Vorstandsvorsitzenden Dr. Selwyn Ho und Bestellung von Ralph Schäfer als VorstandJuly 18, 2025 | finanznachrichten.deTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 11 at 1:00 AM | Reagan Gold Group (Ad)Medigene verlässt Prime Standard wegen InsolvenzverfahrenJune 13, 2025 | finanznachrichten.dePTA-News: Medigene AG: Medigene AG hat Eröffnung des Insolvenzverfahrens beantragt - Einberufung zur aoHV nach §92 AktG entfälltApril 29, 2025 | finanznachrichten.dePTA-Adhoc: Medigene AG: Medigene AG stellt Antrag auf Eröffnung eines InsolvenzverfahrensApril 7, 2025 | finanznachrichten.deMedigene Files Patent for Unique NK-Specific TCR Construct with European Patent OfficeMarch 13, 2025 | markets.businessinsider.comMedigene and EpimAb to develop T cell engagers for solid tumoursFebruary 28, 2025 | finance.yahoo.comSee More Headlines MDG1 Stock Analysis - Frequently Asked Questions How have MDG1 shares performed this year? Medigene's stock was trading at €0.13 at the beginning of the year. Since then, MDG1 stock has increased by 0.0% and is now trading at €0.13. What other stocks do shareholders of Medigene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX) and Ampio Pharmaceuticals (AMPE). Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MDG1 CIKN/A Webwww.medigene.de Phone+49-89-2000330FaxN/AEmployees76Year FoundedN/AProfitability EPS (Trailing Twelve Months)(€0.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.12Net Income-€4.67 million Net Margins-268.10% Pretax MarginN/A Return on Equity-55.69% Return on Assets-27.15% Debt Debt-to-Equity Ratio14.00 Current Ratio2.53 Quick Ratio5.85 Sales & Book Value Annual Sales€7.24 million Price / Sales0.14 Cash Flow€0.10 per share Price / Cash Flow1.37 Book Value€1.72 per share Price / Book0.08Miscellaneous Outstanding Shares7,619,243Free FloatN/AMarket Cap€1.02 million OptionableNot Optionable Beta0.84 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (ETR:MDG1) was last updated on 6/11/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medigene AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Medigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDG1 Stock Alerts